: 2020.1.20 월 18:34
Medi pharm IN
Clinical 학술 Selection
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), toda...
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene(ASTMH) 68th Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) toda...
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
OSAKA, JAPAN--(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will h...
Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announce...
Vargatef plus docetaxel could be an option after failure of immunotherapy in lung cancer
Boehringer Ingelheim announced today the first interim results of VARGADO, ...
Sanofi Appoints Eun-Ju Kim as Head of HR in Korea
Nov. 27, 2018, Seoul –Sanofi-aventis Korea(County Chair: kay Bay, her...
Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Takeda Pharmaceutical Company Limited (TSE: 4502) announced that it will pr...
Boehringer Ingelheim and Lilly present full results of Trajenta’s CARMELINA cardiovascular outcome trial
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented ...
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University in Beijing announce a collabor...
Takeda Announces Phase 3 Trial of ALUNBRIG Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK
Takeda Pharmaceutical Company Limited (TSE: 4502) announced that the global...
Phase 3 Trial of NINLARO as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the ...
South Korea’s National Soccer Team Prepared 2018 Russia World Cup with Vaccination
Sanofi Pasteur in Korea(General Manager: Baptiste de Clarens) announced tha...
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries
Family-owned pharmaceutical company Boehringer Ingelheim today presented it...
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
Boehringer Ingelheim today announced an increase in funding for its corpora...
AstraZeneca’s Calquence Shows Potential in Chronic Lymphocytic Leukaemia Trials
AstraZeneca and Acerta Pharma, its haematology research and development cen...
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
(Business Wire/Korea Newswire) AstraZeneca today presented new data from a ...
Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited [TSE: ...
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential
(Business Wire/Korea Newswire) Boehringer Ingelheim today announced the lau...
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
(Business Wire/Korea Newswire) Takeda Pharmaceutical Company Limited (TSE: ...
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (d...
명칭 : (주)메디컬헤럴드
정기간행물 등록번호 : 서울 아 00603
등록일 : 2008년 6월 23일
제호 : 메디컬헤럴드(The Medical Herald)
발행·편집인 : 우정헌
주소: (우 06178) 서울특별시 강남구 테헤란로 84길 14 지어로빌딩 10층
발행일 : 2008년 4월 1일
전화 : 02-555-7482
팩스 : 02-565-0938
청소년보호책임자 : 우정헌
(우)05836 서울 송파구 법원로 9길 26 1017호 메디컬 미디어 연구소(에이치비지니스파크, 문정동)
2020 메디컬헤럴드. All rights reserved.
Back to Top